Home » Business News » 2013 » June » June 24, 2013

CellaVision appoints new heads of Quality Assurance and Scientific Affairs

June 24, 2013 - London

CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care services, strengthens its organization with new positions in quality and scientific affairs. Göran Granqvist has been appointed VP Quality, responsible for Quality Assurance and part of the management team. Hans-Inge Bengtsson takes a new role as Director Scientific Affairs.

"We are further strengthening our efforts within product development, production and distribution. Good results in quality assurance and scientific affairs lead to the recognition of our products' clinical value," says Yvonne Mårtensson, CEO of CellaVision.

Göran Granqvist will be part of the CellaVision management team and will take overall responsibility for the Group's quality policy, regulatory work in international markets and process development. Göran Granqvist has a broad experience in quality work from his 13 years at Gambro, including positions such as Manager Design Validation and Director R&D Engineering. Prior to his experiences at Gambro Mr Granqvist has worked with quality issues in the nuclear industry and the defense industry. Mr Granqvist leaves a position at ÅF as Manager Quality Assurance & Validation to take on his new role at CellaVision in the fall of 2013.

On April 1, 2013 Hans-Inge Bengtsson took the position as Director Scientific Affairs with global responsibility for clinical research and development of CellaVision's products in the field of hematology. Hans-Inge has participated in several scientific articles on CellaVision products and comes from a position as Quality Manager of CellaVision. He has a degree in Chemical Engineering and has many years of experience in research and development, regulatory affairs, clinical laboratory and pharmaceutical. Previous jobs include HemoCue AB and PolyPeptide Laboratories AB.

For photos, please press links below.

For more information, please contact
Yvonne Mårtensson, CEO, CellaVision AB
Tel:+46 708-33 77 82 | Email:  

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at

Photo Göran Granqvist
Photo Hans-Inge Bengtsson

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: CellaVision AB via Thomson Reuters ONE



Comment on this story